Cargando…

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression

BACKGROUND: There is an acute need to uncover biomarkers that reflect the molecular pathologies, underpinning prostate cancer progression and poor patient outcome. We have previously demonstrated that in prostate cancer cell lines PDE4D7 is downregulated in advanced cases of the disease. To investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Böttcher, R, Henderson, D J P, Dulla, K, van Strijp, D, Waanders, L F, Tevz, G, Lehman, M L, Merkle, D, van Leenders, G J L H, Baillie, G S, Jenster, G, Houslay, M D, Hoffmann, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815894/ https://www.ncbi.nlm.nih.gov/pubmed/26575822 http://dx.doi.org/10.1038/bjc.2015.335

Ejemplares similares

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status
por: van Strijp, Dianne, et al.
Publicado: (2019)

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes
por: van Strijp, Dianne, et al.
Publicado: (2018)

Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region
por: Gulliver, Chloe, et al.
Publicado: (2023)

Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG
por: Roberts, Justin M., et al.
Publicado: (2017)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners
por: Houslay, Kirsty F., et al.
Publicado: (2017)

Retracted: Phosphorylation of PDE4A5 by MAPKAPK2 attenuates fibrin degradation via p75 signalling
por: Houslay, K F, et al.
Publicado: (2019)

The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus
por: Byrne, Ashleigh M., et al.
Publicado: (2015)

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
por: Li, Xiangyi, et al.
Publicado: (2018)

PDE4D and PDE4B Function in Distinct Subcellular Compartments in Mouse Embryonic Fibroblasts
por: Blackman, Brigitte E., et al.
Publicado: (2011)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5
por: Bolger, Graeme B, et al.
Publicado: (2002)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

PDE4D regulates Spine Plasticity and Memory in the Retrosplenial Cortex
por: Baumgärtel, Karsten, et al.
Publicado: (2018)

A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice
por: Fortin, Marylène, et al.
Publicado: (2009)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System
por: Zhang, Chong, et al.
Publicado: (2017)

Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model
por: Boomkamp, S D, et al.
Publicado: (2014)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020)

Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
por: Wang, Qiong, et al.
Publicado: (2022)

Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis
por: Liao, Yi-Chu, et al.
Publicado: (2010)

The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes
por: Gulliver, Chloe, et al.
Publicado: (2022)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions
por: Bernreuther, Christian, et al.
Publicado: (2020)

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
por: Nam, R K, et al.
Publicado: (2007)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies
por: Gulliver, Chloe, et al.
Publicado: (2023)

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
por: Bolger, Graeme B., et al.
Publicado: (2015)

TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation
por: Casey, Orla M., et al.
Publicado: (2012)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9fsa68k4sd71a60r9h9ue3c56p